Direct-Acting Antiviral Therapy Has Reduced HCV Prevalence Over Time Among Patients With HIV, Study Suggests

Infectious Disease Advisor (4/14, Nye) reports a study suggests that “the prevalence of hepatitis C virus (HCV) has decreased over time among patients with HIV (PWH) infection in the United States with the use of direct-acting antiviral (DAA) therapy.” Researchers observed “the disparity in HCV prevalence across demographic groups was less pronounced in the current DAA era than in the early” and interferon-based eras. They concluded, “Although progress has been made in HCV care among PWH, our findings underscore the continued importance of prioritizing HCV testing and treatment in all PWH, especially in certain key groups.” The study was published in Open Forum Infectious Diseases.